Shanghai Haoyuan Chemexpress Co., Ltd. (SHA:688131)
88.83
-3.12 (-3.39%)
Sep 4, 2026, 3:00 PM CST
SHA:688131 Revenue
Shanghai Haoyuan Chemexpress had revenue of 919.32M CNY in the quarter ending June 30, 2026, with 30.43% growth. This brings the company's revenue in the last twelve months to 3.21B, up 27.26% year-over-year. In the year 2025, Shanghai Haoyuan Chemexpress had annual revenue of 2.88B with 26.73% growth.
Revenue (ttm)
3.21B
Revenue Growth
+27.26%
P/S Ratio
5.89
Revenue / Employee
766.13K
Employees
4,195
Market Cap
18.94B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.88B | 606.72M | 26.73% |
| Dec 31, 2024 | 2.27B | 390.13M | 20.75% |
| Dec 31, 2023 | 1.88B | 521.99M | 38.44% |
| Dec 31, 2022 | 1.36B | 388.83M | 40.12% |
| Dec 31, 2021 | 969.23M | 334.12M | 52.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harbin Pharmaceutical Group | 16.14B |
| Joincare Pharmaceutical Group Industry | 13.90B |
| China Resources Double-Crane Pharmaceutical | 10.80B |
| Livzon Pharmaceutical Group | 10.75B |
| Kangmei Pharmaceutical | 4.97B |
| Chengdu Kanghong Pharmaceutical Group | 4.31B |
| Betta Pharmaceuticals | 3.85B |
| Jilin Aodong Pharmaceutical Group | 2.24B |